BioAlliance Pharma to Resubmit Loramyc(R) NDA in the Second Quarter of 2009

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections, on cancer and on AIDS, today announced that based on a recent ad hoc meeting held with the FDA, the NDA for Loramyc® will be resubmitted in the second quarter of 2009. If approved, Par Pharmaceutical/Strativa, BioAlliance Pharma’s partner for Loramyc commercialization in the USA, could launch Loramyc® in the second half of 2010.